Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome

• Status: Not yet recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the drug absorption of oral antibiotics in patients with short bowel syndrome.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Central Hospital, Nancy, France
• Collaborators: FIlière des Maladies rares Abdomino-THOraciques; Fresenius Kabi; Société Francophone Nutrition Clinique et Métabolisme
• Treatments: Amoxicillin; Levofloxacin; Ofloxacin; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination

Criteria

Inclusion Criteria:

• Short bowel syndrome

• Treated for a documented infection with antibiogram by amoxicillin (+/- clavulanic acid)or ofloxacin or levofloxacin or sulfamethoxazole/trimethoprim

• Hospitalized in the Nutritional Assistant Unit or the Infectiology Unit of the Regional University Hospital of Nancy

• Affiliated to a social security system

• Having received an physical examination before entering study

• Having received full information regarding the study organization and having signed the informed consent

Exclusion Criteria:

• Patient at risk of worsening their oral absorption abilities during study

• Patient requiring dialysis

• Women of childbearing age without efficient birth control

• Allergy to any of the drugs tested

• Person concerned by Articles L. 1121-5, L. 1121-7 et L1121-8 of the Code of public health

• Person deprived of liberty or person undergoing psychiatric care pursuant to articles L. 3212-1 et L. 3213-1